arrow
P

Patricia Galván

Oak Crest Institute of Science
H指数:37
被引数:6,586

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical Pharmacokinetics of a Triple-Combination Intravaginal Ring for HIV Prevention

HIV预防用三联组合阴道环的体外药代动力学

2026-07-280
OA
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy

Ki67动态变化可预测接受术前内分泌治疗的雌激素受体阳性/HER2阴性乳腺癌患者的内分泌敏感性。

2025-10-160
OAAI
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效:SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

2025-09-300
OAAI
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer

雌激素受体阳性、HER2阴性乳腺癌年轻女性的基因组与临床特征

2025-09-240
PREAI
Preoperative Radiotherapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results from the YOUNGSTER Trial

术前放疗诱导的分子和免疫调控在早期乳腺癌中的作用:YOUNGSTER试验的结果

2025-08-050
OA
Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review

紫杉醇相关性Kounis综合征I型:1例年轻HER2阳性乳腺癌患者报告及基因组学在阐明复杂治疗情境中作用:病例报告及综述

BREAST
IF7.9
2025-06-010
OAAI
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

HER2DX ERBB2 mRNA评分:用于接受化疗、曲妥珠单抗和帕妥珠单抗治疗的一线晚期HER2阳性乳腺癌

2025-04-250
OA
Correlation of the HER2DX Genomic Test withPathologic Features in Early-Stage HER2+BreastCancer
2025-03-010
PRE
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
2024-07-111
OAAI
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
2024-07-112
OAAI
Characterizing Immune Infiltration in Metastatic Hormone Receptor-Positive/HER2Negative Breast Cancer: A Comprehensive Translational Analysis from four SOLTI Clinical Trials
2024-05-020
PRE
Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
2024-05-020
PRE
Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
2024-05-020
PRE
Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor- positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
2024-05-020
PRE
Solti-1716 TATEN phase II trial: Targeting non-Luminal disease by PAM50 with pembrolizumab and paclitaxel in Hormone Receptor-positive/HER2-negative advanced breast cancer (ABC)
2024-05-020
PRE
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
2024-04-081
OAAI
Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial
2024-03-220
PRE